A dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and obesity.
AIMS: This real-world study compared clinical outcomes between tirzepatide treatment and bariatric metabolic surgery (BMS) in adults with obesity. METHODS: This retrospective cohort study used the TriNetX network to identify adults with a body mass i…
BACKGROUND: The use of ChatGPT in healthcare is still in its early stages; however, it has the potential to become a cornerstone in modern healthcare systems. This study aims to assess the accuracy of output of ChatGPT compared with those of CareNote…
BACKGROUND: Tirzepatide, a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, has shown significant cardiovascular benefits in clinical trials. This study investigates the real-world impa…
Tirzepatide, a dual agonist for glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors used in type 2 diabetes and obesity management, was investigated for its effects on glioma cells, focusing on its potenti…
Tirzepatide, a dual GIP/GLP-1 receptor agonist, has shown unprecedented efficacy in weight loss and improving metabolic parameters in clinical trials. However, the durability of these benefits after treatment cessation remains poorly understood. This…
This report describes the first case of maturity-onset diabetes in young (MODY) with HNF1B mutation started administration of the dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, tirzepatide. A 26-year-o…
PURPOSE: Large telehealth companies and smaller aesthetic medicine providers used compounded semaglutide and tirzepatide to meet consumer demand for these drugs during their shortages. In this study, we estimate the documentation rate of compounded f…
Obesity prevalence is rapidly increasing worldwide, necessitating diverse treatment approaches ranging from pharmacotherapy to surgical interventions. Tirzepatide, a recently approved dual GIP/GLP-1 receptor agonist, has shown therapeutic promise, bu…
Type 2 diabetes and obesity drive significant morbidity, mortality, and health care costs in the United States. Clinicians increasingly prescribe glucagon-like peptide 1 (GLP1) receptor agonists (GLP1-RAs) and dual GLP1 and glucose-dependent insulino…
BACKGROUND: Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, causes considerable weight loss, but d…
Glucagon-like peptide-1 receptor agonist (GLP-1RA) has attracted attention owing to its hypoglycemic and weight-loss effects, and various dosage forms are available in the market. Recently, glucose-dependent insulin secretion-stimulating polypeptide…
BACKGROUND AND HYPOTHESIS: In patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), there remains a paucity of data from large high-quality real-world studies on the efficacy of weight-lowering interventions, including the g…
BACKGROUND: This meta-analysis aimed to evaluate the relation between tirzepatide exposure and the risk of adverse cardiovascular or renal events in participants with type 2 diabetes mellitus (T2DM) or obesity. METHODS: A comprehensive search was con…
BACKGROUND: Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 diabetes is unknown. METHODS: In this phase…
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have experienced rapid growth in recent years as treatments for type 2 diabetes mellitus and obesity. These medications offer promising benefits, including weight loss and improved glycemic control…
BACKGROUND: Obesity is a global public health challenge. Pharmacological interventions, such as glucagon-like peptide-1 (GLP-1) receptor agonists (eg, semaglutide) and dual GLP-1/gastric inhibitory polypeptide receptor agonists (eg, tirzepatide), hav…
While Zepbound (Tirzepetide) is the only FDA-approved drug for obstructive sleep apnea (OSA), pharmacological options remain limited. Emerging data suggest sodium glucose co-transporter (SGLT-2) inhibitors may offer a novel therapeutic benefit in thi…
INTRODUCTION: Tirzepatide is one of the commonly used combined glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) agonists for weight loss in recent years. There are significant advantages of these medications for…